Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603574 | 1.00 | HRH4 (0.62) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL3813324 | 0.85 | HRH4 (0.60) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL3813320 | 0.85 | HRH4 (0.60) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL604783 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL18550564 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL606357 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL604782 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL18550565 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL601997 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 | |
| SCHEMBL604373 | 0.80 | HRH4 (0.64) | HRH4HRH3HTR3AROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278311-B2 | Substituted pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20090270364-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270364-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | HRH4 1147/4885HRH3 713/4885HTR3A 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.